Immunome stock gains as analyst targets highlight upside potential

Published on 09/19/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunome stock is trading near the top of its 52-week range as of August 20, 2026, while analysts see further upside with a 12-month average target of USD 36.31. Recent market cap data show Immunome valued at about USD 2.80 billion in September 2026.

IMNM, US45254C1062, Illustration mit AI erstellt.

Immunome stock (ISIN US45254C1062) is trading close to its recent highs, with the shares priced at USD 29.83 on Nasdaq as of August 20, 2026, matching the prior close and underscoring solid momentum in the name.

Analysts see double-digit upside

According to Investing.com on August 20, 2026, Immunome stock carries a 12-month average analyst price target of USD 36.31, implying upside of 21.72% from the quoted level of USD 29.83.

As the same overview from Investing.com reports, the highest target among analysts stands at USD 40.00 while the lowest is USD 30.00, and 14 analysts rate the shares as a Buy with none recommending a Sell, resulting in an overall Strong Buy consensus.

Stock trades near 52-week high

Per data cited by Investing.com with prices as of August 20, 2026, Immunome stock changed hands at USD 29.83 with a daily trading range between USD 27.63 and USD 30.06, and a 52-week range between USD 8.66 and USD 30.06, placing the shares right at the top of their one-year band.

Market capitalization figures compiled by CompaniesMarketCap show Immunome valued at about USD 2.80 billion as of September 12, 2026, positioning the company as the 4,341st most valuable listed firm worldwide by this metric.

Earnings calendar and investor focus

According to the event data provided by Investing.com, Immunome is scheduled to release its next earnings report on November 16, 2026, a date that many investors will watch closely for updates on the company's pipeline progress and financial trajectory.

For investors, the combination of the stock trading near its 52-week high, a market capitalization of around USD 2.80 billion as of mid-September 2026, and a Strong Buy consensus with an average target of USD 36.31 provides a clear numerical framework for assessing risk and potential reward around Immunome stock.

Price snapshot for Immunome stock

Immunome stock most recently closed at USD 29.83 on Nasdaq on August 20, 2026, with that level sitting just below the 52-week high of USD 30.06 and far above the 52-week low of USD 8.66, illustrating the substantial re-rating the shares have undergone over the past year.